A Targeted Approach to Neuropathic Pain

A first-in-class, non-viral DNA plasmid therapy designed to silence Nav1.7

Chronic Neuropathic Pain

impacts over 820 million people worldwide. Current treatments offer modest relief, require daily dosing, and often carry serious systemic side effects or addiction risk.

Most therapies treat symptoms, not the root cause.

We are the Solution

Pinco Biotherapeutics is developing a DNA plasmid-based therapy engineered to selectively reduce expression of Nav1.7, a genetically validated driver of pain signaling. Our plasmid is:

Nav1.7 is selectively enriched in DRG neurons responsible for pain signaling. Our construct incorporates cell-specific promoters and shRNA targeting to minimize off-target sodium channel suppression and systemic exposure. The goal is precise modulation of the pain pathway — without impacting unrelated sodium channel subtypes in cardiac or CNS tissue.

Specific.

Rather than transient receptor inhibition, our therapy suppresses Nav1.7 expression at the gene level with the potential to provide weeks to months of modulation from a single administration. This durability could reduce dosing frequency, improve compliance, and meaningfully differentiate from daily oral therapies. Longer-lasting effect also creates clear clinical and commercial value inflection.

Durable.

Our platform eliminates viral capsid proteins, reducing immunogenicity risk and avoiding the redosing limitations seen with AAV-based gene therapies. By using a non-viral plasmid construct, we aim to improve tolerability, simplify regulatory complexity, and reduce long-term safety uncertainty. This approach is engineered to deliver genetic precision without viral baggage.